GHRP-2 triggered growth hormone release in mice whose normal GH-releasing pathway was genetically disabled, proving it works through an independent mechanism.
9× baseline GHGHRP-2 raised growth hormone from 1.0 to 9.3 ng/ml in mice with non-functional GHRH receptors — proving GHRH-independent activity
What the researchers found
GHRP-2 (growth hormone-releasing peptide-2) stimulated significant growth hormone release in 'little' (lit/lit) mice that have mutated, non-functional GHRH receptors — proving that GHRP-2 can trigger growth hormone release independently of the GHRH signaling pathway. Lit/lit mice injected with 10 mcg GHRP-2 released 9.3±1.5 ng/ml GH vs 1.04±1.15 ng/ml in controls (p<0.001).
Heterozygous lit/+ mice showed intermediate GH release (34.5±9.7 ng/ml), while wild-type mice had the highest response (163±46 ng/ml). This dose-response pattern across genotypes demonstrates that GHRP-2's effect is partially but not fully dependent on GHRH signaling — it works through a separate pathway via the ghrelin receptor (GHS-R1a) on remaining pituitary somatotroph cells.
Why it matters
This study proves that growth hormone-releasing peptides like GHRP-2 have their own independent pathway for stimulating growth hormone, separate from the traditional GHRH system. This means GHRP-2 could potentially help patients whose growth hormone deficiency is caused by GHRH receptor problems — a subset of GH-deficient individuals who wouldn't respond to GHRH-based therapies.
The numbers in context
GHRP-2 dose: 10 mcg · lit/lit GH response: 9.3±1.5 ng/ml vs 1.04±1.15 controls · lit/+ response: 34.5±9.7 ng/ml · Wild-type: 163±46 ng/ml · p<0.001
How the study worked
Researchers compared acute growth hormone response to injected GHRP-2 in three groups of mice: lit/lit mice (homozygous for GHRH receptor mutation, severe GH deficiency), lit/+ heterozygous littermates (intermediate GH function), and wild-type C57BL/6J mice. Serum growth hormone was measured after 10 mcg GHRP-2 injection. Plasma leptin and ghrelin levels were also evaluated at baseline and after stimulation.
Who was studied
Three groups of C57BL/6J mice: GH-deficient lit/lit, heterozygous lit/+, and wild-type +/+
What this study cannot tell us
Mouse model — the magnitude of GHRP-2's GHRH-independent effect may differ in humans. The lit/lit mouse model is a specific genetic form of GH deficiency that doesn't represent all causes. The study used a single acute dose, not chronic treatment. The GH response in lit/lit mice, while statistically significant, was very small compared to wild-type (9.3 vs 163 ng/ml), raising questions about clinical meaningfulness.
How to read the evidence
This is a well-designed animal study using a genetic model to isolate a specific signaling pathway. The results clearly demonstrate GHRH-independent GH release, though the clinical relevance of the small absolute GH response in lit/lit mice is uncertain.
When this study was published
Published in 2012, this study provides foundational mechanistic evidence that remains relevant to understanding how GHRPs and ghrelin mimetics work. The core finding about GHRH-independent action has been supported by subsequent research.
The bigger picture
Growth hormone-releasing peptides (GHRPs) like GHRP-2 and GHRP-6, along with oral ghrelin mimetics like MK-677, are widely discussed in the peptide community. This study provides fundamental mechanistic evidence that these peptides don't simply amplify GHRH signaling — they have their own independent pathway through the ghrelin receptor. This dual-pathway architecture explains why combining GHRPs with GHRH analogs produces synergistic GH release, and has implications for treating different types of growth hormone deficiency.
Questions still open
- Could GHRP-2 provide therapeutic benefit for patients with GHRH receptor mutations, despite the relatively small GH response compared to normal?
- Does chronic GHRP-2 treatment increase the residual GH response over time in GHRH-insensitive models?
- How do other ghrelin receptor agonists (GHRP-6, hexarelin, MK-677) compare to GHRP-2 in GHRH-independent GH release?
Common questions
What is GHRP-2 and how does it differ from GHRH?
What are 'little mice' and why are they useful for this research?
Read the original research
Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice.
Clinics (Sao Paulo, Brazil), 67(3), 265-72
Citation
Peroni, Cibele N; Hayashida, Cesar Y; Nascimento, Nancy; Longuini, Viviane C; Toledo, Rodrigo A; Bartolini, Paolo; Bowers, Cyril Y; Toledo, Sergio P A. (2012). Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice.. Clinics (Sao Paulo, Brazil), 67(3), 265-72.